Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Thiotepa Generic Name & Formulations
Legal Class
Rx
General Description
Thiotepa 15mg; per vial; lyophilized pwd for IV, intravesical, or intracavitary administration after reconstitution.
Pharmacological Class
Alkylating agent.
How Supplied
Contact supplier.
Manufacturer
Thiotepa Indications
Indications
Superficial papillary carcinoma of the urinary bladder. Intracavitary effusion due to neoplasm of serosal cavities.
Thiotepa Dosage and Administration
Adult
Avoid fluids 8–12 hrs prior to treatment. 60mg once weekly for 4 weeks; may repeat up to a total of 3 courses. Retain in bladder for 2 hours. Intracavitary administration: 0.6–0.8mg/kg through same tube used to remove fluid from cavity.
Children
Not recommended.
Thiotepa Contraindications
Contraindications
Renal, hepatic, or bone marrow dysfunction; if need outweighs risk, may be used in low dosage with close monitoring.
Thiotepa Boxed Warnings
Not Applicable
Thiotepa Warnings/Precautions
Warnings/Precautions
Bone marrow suppression; monitor blood and platelets weekly during and for at least 3 weeks after therapy. Discontinue if WBC ≤3000/mm3 or platelets ≤150,000/mm3. Monitor renal and hepatic function. Use effective contraception if patient or partner is of childbearing potential. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Thiotepa Pharmacokinetics
See Literature
Thiotepa Interactions
Interactions
Increased toxicity with concomitant or sequential alkylating agents (nitrogen mustards, cyclophosphamide), radiation, myelosuppressants. Prolonged apnea with succinylcholine.
Thiotepa Adverse Reactions
Adverse Reactions
Myelosuppression, fatigue, febrile or allergic reactions, inj site reactions, urinary retention, dysuria, GI disturbances, anorexia, alopecia, dizziness, headache, drowsiness, blurred vision, amenorrhea, interferes with spermatogenesis. Intravesical administration: rare: chemical or hemorrhagic cystitis.
Thiotepa Clinical Trials
See Literature
Thiotepa Note
Notes
Formerly known under the brand name Thioplex.
Thiotepa Patient Counseling
See Literature
Thiotepa Generic Name & Formulations
Legal Class
Rx
General Description
Thiotepa 15mg; per vial; lyophilized pwd for IV, intravesical, or intracavitary administration after reconstitution.
Pharmacological Class
Alkylating agent.
How Supplied
Contact supplier.
Manufacturer
Thiotepa Indications
Indications
Adenocarcinomas of the breast. Intracavitary effusion due to neoplasm of serosal cavities.
Thiotepa Dosage and Administration
Adult
0.3–0.4mg/kg IV once every 1–4 weeks. Intracavitary administration: 0.6–0.8mg/kg through same tube used to remove fluid from cavity.
Children
Not recommended.
Thiotepa Contraindications
Contraindications
Renal, hepatic, or bone marrow dysfunction; if need outweighs risk, may be used in low dosage with close monitoring.
Thiotepa Boxed Warnings
Not Applicable
Thiotepa Warnings/Precautions
Warnings/Precautions
Bone marrow suppression; monitor blood and platelets weekly during and for at least 3 weeks after therapy. Discontinue if WBC ≤3000/mm3 or platelets ≤150,000/mm3. Monitor renal and hepatic function. Use effective contraception if patient or partner is of childbearing potential. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Thiotepa Pharmacokinetics
See Literature
Thiotepa Interactions
Interactions
Increased toxicity with concomitant or sequential alkylating agents (nitrogen mustards, cyclophosphamide), radiation, myelosuppressants. Prolonged apnea with succinylcholine.
Thiotepa Adverse Reactions
Adverse Reactions
Myelosuppression, fatigue, febrile or allergic reactions, inj site reactions, urinary retention, dysuria, GI disturbances, anorexia, alopecia, dizziness, headache, drowsiness, blurred vision, amenorrhea, interferes with spermatogenesis. Intravesical administration: rare: chemical or hemorrhagic cystitis.
Thiotepa Clinical Trials
See Literature
Thiotepa Note
Notes
Formerly known under the brand name Thioplex.
Thiotepa Patient Counseling
See Literature
Thiotepa Generic Name & Formulations
Legal Class
Rx
General Description
Thiotepa 15mg; per vial; lyophilized pwd for IV, intravesical, or intracavitary administration after reconstitution.
Pharmacological Class
Alkylating agent.
How Supplied
Contact supplier.
Manufacturer
Thiotepa Indications
Indications
Adenocarcinomas of the ovary. Intracavitary effusion due to neoplasm of serosal cavities.
Thiotepa Dosage and Administration
Adult
0.3–0.4mg/kg IV once every 1–4 weeks. Intracavitary administration: 0.6–0.8mg/kg through same tube used to remove fluid from cavity.
Children
Not recommended.
Thiotepa Contraindications
Contraindications
Renal, hepatic, or bone marrow dysfunction; if need outweighs risk, may be used in low dosage with close monitoring.
Thiotepa Boxed Warnings
Not Applicable
Thiotepa Warnings/Precautions
Warnings/Precautions
Bone marrow suppression; monitor blood and platelets weekly during and for at least 3 weeks after therapy. Discontinue if WBC ≤3000/mm3 or platelets ≤150,000/mm3. Monitor renal and hepatic function. Use effective contraception if patient or partner is of childbearing potential. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Thiotepa Pharmacokinetics
See Literature
Thiotepa Interactions
Interactions
Increased toxicity with concomitant or sequential alkylating agents (nitrogen mustards, cyclophosphamide), radiation, myelosuppressants. Prolonged apnea with succinylcholine.
Thiotepa Adverse Reactions
Adverse Reactions
Myelosuppression, fatigue, febrile or allergic reactions, inj site reactions, urinary retention, dysuria, GI disturbances, anorexia, alopecia, dizziness, headache, drowsiness, blurred vision, amenorrhea, interferes with spermatogenesis. Intravesical administration: rare: chemical or hemorrhagic cystitis.
Thiotepa Clinical Trials
See Literature
Thiotepa Note
Notes
Formerly known under the brand name Thioplex.
Thiotepa Patient Counseling
See Literature
